Novo Nordisk 18 may 2026 Supreme Court declines to hear IRA challenges from Novo, AZ and more - Fierce Pharma
Novo Nordisk 18 may 2026 Meta founder’s biotech bets on AI to cut costs for Parkinson’s cell therapy - Новости GxP
Novo Nordisk 15 may 2026 Novo Nordisk and ASN Foundation award obesity and metabolic research advances - Nutrition Insight
Novo Nordisk 13 may 2026 Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders - Clinical Trials Arena
Novo Nordisk 12 may 2026 Biopharma bites: Rigel buys beleaguered PROTAC, Bayer's pipeline trim, and more from Novo Nordisk, Delos Capital - FirstWord Pharma
Novo Nordisk 12 may 2026 Cellular Intelligence acquires Novo Nordisk's cell therapy program for Parkinson's - The Pharma Letter
Novo Nordisk 12 may 2026 AI to accelerate Novo Nordisk's Parkinson’s cell therapy - European Pharmaceutical Review
Novo Nordisk 12 may 2026 Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight - WSJ
Novo Nordisk 11 may 2026 Cellular Intelligence has AI plans for Novo Nordisk's cell therapy castoff - FirstWord Pharma
Novo Nordisk 11 may 2026 Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy - Reuters
Novo Nordisk 11 may 2026 Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech - Fierce Biotech
Novo Nordisk 8 may 2026 Novo Nordisk does not expect the Chinese patent for semaglutide to expire until 2027 - medwatch.com
Novo Nordisk 7 may 2026 Novo Nordisk Beats First-Quarter Estimates on Oral Wegovy Demand - thelec.net
Novo Nordisk 6 may 2026 Novo Nordisk Could Win the Oral GLP-1 Race Against Lilly. Why It Just Raised Guidance. - Barron's
Novo Nordisk 6 may 2026 Novo CEO cites pricing 'sweet spot' as Wegovy pill debuts with $355M quarter - Fierce Pharma